RFA-CA-24-020: Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants of up to $1.6 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on September 26, 2024.
From the official notice on Grants.gov, last changed March 27, 2024. Checked November 7, 2026.
- Award ceiling$1.6 million
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU54
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$256,448
- Typical project length5 years
- U54, Specialized Center Cooperative Agreement. A research center with several projects and shared cores, with substantial NIH involvement. Other open U54 notices.
Projects funded under RFA-CA-24-020 were run by National Cancer Institute (NCI, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-24-020 in the NIH Guide.
Key dates
| Posted | March 27, 2024 |
|---|---|
| Deadline | September 26, 2024 |
| Archived by Grants.gov | November 1, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $256,448; it allows up to $1.6 million per award.
- Most of the program's money (57% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of the U54 CHD-MH SPORE Program is to fund a network of multi-disciplinary, multi-institutional translational research SPOREs uniquely focused on 1) health disparities and/or minority health research and 2) the development of novel-cancer relevant interventions in underserved populations with cancer or at risk for cancer.
Funded under RFA-CA-24-020 so far
NIH funded 5 projects under RFA-CA-24-020 in fiscal 2025 to 2026, at 5 institutions. The median yearly award was $256,448.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Lymphoma Outcomes SPORE | University of TX MD Anderson Can Ctr | 2026 | $2.4 million |
| Core C: Biostatistics & Bioinformatics Core | University of Miami School of Medicine | 2026 | $125,532 |
| Core B: Biospecimen Processing and Storage | Baylor College of Medicine | 2026 | $124,667 |
| Core A: Administrative Core | University of California, San Francisco | 2026 | $165,607 |
| Core A: Biospecimens and Pathology Core | Univ of North Carolina Chapel Hill | 2026 | $192,067 |
Who has won Cancer Treatment Research grants before
From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 144 | $188 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 68 | $185 million |
| Icahn School of Medicine at Mount Sinai | New York | 35 | $179 million |
| Public Health Institute | California | 4 | $168 million |
| Fred Hutchinson Cancer Center | Washington | 57 | $156 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-24-020 still open?
No. It closed on September 26, 2024.
Who can apply for Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional)?
Closed September 26, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.6 million each.
Who has been funded under RFA-CA-24-020?
NIH RePORTER lists 5 projects funded under RFA-CA-24-020 in fiscal 2025 to 2026, at 5 institutions. The most were at University of TX MD Anderson Can Ctr, University of Miami School of Medicine, Baylor College of Medicine.
Who has won Cancer Treatment Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, Inc., Icahn School of Medicine at Mount Sinai. The program made 3,622 awards worth $5.6 billion in that time.
Similar open grants
- Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)
- Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)
- Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
- Health and Extreme Weather Solutions-Focused Research Hubs (U54 - Clinical Trial Optional)
- George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
- Limited Competition: The NHGRI Analysis, Visualization, and Informatics Lab-space (AnVIL) (U54 Clinical Trial Not Allowed)